Ads
related to: hypereosinophilic syndrome prevalence statistics- HES Treatment Option
Read About An Option To Treat HES
And Request A Representative Today.
- Dosing & Administration
View Dosing And Administration
Information For An HES Treatment.
- Identifying Patients
Discover What Your Peers Are Saying
About An HES Treatment Option.
- Clinical Study Info
Learn About The Clinical Study Info
Regarding An HES Treatment Option.
- Mechanism Of Action Info
Read Information About The MOA
Of A Treatment Option For HES.
- Reimbursement Information
Help Get Your Patients Started With
An HES Treatment Today.
- HES Treatment Option
Search results
Results From The WOW.Com Content Network
Hypereosinophilic syndrome is a disease characterized by a ... estimated the prevalence of HES at the time of granting orphan drug ... Statistics; Cookie statement;
Reslizumab, a newly developed antibody directed against interleukin 5 that has been successfully used to treat 4 patients with the hypereosinophilic syndrome, may also be of use for lymphocyte-variant eosinophilia. [4] [5] [10] [11] Patients suffering minimal or no disease complications have gone untreated. [4]
The age-adjusted incidence of hypereosinophilic syndrome/chronic eosinophilic leukemia reported by the International Classification of Diseases for Oncology (Version 3) is ~0.036 per 100,000 with the mean frequency of FIP1L1-PDGFRA gene fusions occurring in ~10% of patients with hypereosinophilia as detected in developed countries. The fused ...
Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues.
The hypereosinophilic syndrome is a sustained elevation in this count above 1.5 × 10 9 /L (i.e. 1,500/μL) that is also associated with evidence of eosinophil-based tissue injury. Eosinophils usually account for less than 7% of the circulating leukocytes. [1]
Familial eosinophilia is a rare congenital disorder characterized by the presence of sustained elevations in blood eosinophil levels that reach ranges diagnostic of eosinophilia (i.e. 500–1500/microliter) or, far more commonly, hypereosinophilia (i.e. >1,500/microliter).
It can arise de novo or may develop in patients having the chronic form of a hypereosinophilic syndrome. Patients with acute eosinophilic leukemia have a propensity for developing bronchospasm as well as symptoms of the acute coronary syndrome and/or heart failure due to eosinophilic myocarditis and eosinophil-based endomyocardial fibrosis.
Idiopathic hypereosinphilic syndrome and lymphocyte-variant hypereosinophilia: corticosteroids; for individuals with these hypereosinophilias that are refractory to or break through corticosteroid therapy and individuals requiring corticosteroid-sparing therapy, recommended alternative drug therapies include hydroxyurea, Pegylated interferon-α ...
Ad
related to: hypereosinophilic syndrome prevalence statistics